MCK241122P590000
- 0.35
- -0.65-65.00%
McKesson Newsroom
AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN (Nilotinib) Tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
McKesson's (NYSE:MCK) Conservative Accounting Might Explain Soft Earnings
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Investors Can Find Comfort In McKesson's (NYSE:MCK) Earnings Quality
McKesson Analyst Ratings
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?
Investors Heavily Search McKesson Corporation (MCK): Here Is What You Need to Know
Citi Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $713
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Ontada Collaborates With Datavant to Enable Faster Access to Market-Leading Oncology Insights
McKesson Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Here's Why McKesson (MCK) Is a Strong Momentum Stock
McKesson, Oracle, Thoma Bravo Among Finalists to Acquire Veradigm: Report
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $668
Express News | Mckesson Corp : UBS Raises Target Price to $708 From $590
Evercore Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $680
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $612 to $688
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike